Jéssyca Milene Ribeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jéssyca Milene Ribeiro has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Larissa Helena Torres
Department of Food and Drugs, Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, MG, Brazil
5 shared publications - Carla Speroni Ceron
Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil
4 shared publications - Silvia Graciela Ruginsk
Department of Physiological Sciences, Biomedical Sciences Institute, Federal University of Alfenas, Alfenas, Brazil
3 shared publications - Alessandra Oliveira Silva
Federal University of Alfenas, Alfenas, Minas Gerais, Brazil
2 shared publications - Antonio Alves Pereira-Júnior
National Institute for Quality Control in Health (INCQS), Oswaldo Cruz Foundation (FIOCRUZ), 21040-361, RJ, Brazil
2 shared publications - Carolina Aparecida de Faria Almeida
Federal University of Alfenas, Brazil
2 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (7) , 9471-9479
Cannabidiol as a treatment for cocaine use disorder: a scoping review
Cocaine use disorder (CUD) remains a major public health challenge with limited effective therapeutic options. Cannabidiol (CBD) has been proposed as a potential treatment due to its neuroprotective and anti-craving properties. This scoping review aims to synthesize and map the existing evidence from clinical trials evaluating CBD’s effects on craving reduction, relapse prevention, cognitive function, and emotional regulation in individuals with CUD. Although CBD was well tolerated and associated with fewer adverse events than conventional pharmacological treatments, clinical studies included in this review did not demonstrate significant efficacy over placebo in reducing cocaine craving, preventing relapse, or improving cognitive performance, despite promising preclinical outcomes. The review also highlights methodological limitations across studies, including variability in dosage, treatment duration, and study design. Although current evidence does not support CBD as a standalone treatment for CUD, its favorable safety profile suggests potential utility within a broader, multimodal therapeutic framework. Future research should prioritize standardized protocols and explore synergistic combinations with behavioral or pharmacological interventions to enhance treatment efficacy.
- 3 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (7) , 9471-9479
Open AccessCannabidiol as a treatment for cocaine use disorder: a scoping review
Cocaine use disorder (CUD) remains a major public health challenge with limited effective therapeutic options. Cannabidiol (CBD) has been proposed as a potential treatment due to its neuroprotective and anti-craving properties. This scoping review aims to synthesize and map the existing evidence from clinical trials evaluating CBD’s effects on craving reduction, relapse prevention, cognitive function, and emotional regulation in individuals with CUD. Although CBD was well tolerated and associated with fewer adverse events than conventional pharmacological treatments, clinical studies included in this review did not demonstrate significant efficacy over placebo in reducing cocaine craving, preventing relapse, or improving cognitive performance, despite promising preclinical outcomes. The review also highlights methodological limitations across studies, including variability in dosage, treatment duration, and study design. Although current evidence does not support CBD as a standalone treatment for CUD, its favorable safety profile suggests potential utility within a broader, multimodal therapeutic framework. Future research should prioritize standardized protocols and explore synergistic combinations with behavioral or pharmacological interventions to enhance treatment efficacy.
- 28 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (6) , 6561-6577
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.
- 28 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (6) , 6561-6577
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.
- 8 September 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (7) , e4119
Curcumin Prevents Renal Damage of l‐NAME Induced Hypertension in by Reducing MMP‐2 and MMP‐9
In the present study, we investigated whether curcumin administration would interfere with the main renal features of l‐NAME‐induced hypertension model. For this purpose, we conducted both in vitro and in vivo experiments to evaluate renal indicators of inflammation, oxidative stress, and metalloproteinases (MMPs) expression/activity. Hypertension was induced by l‐NAME (70 mg/kg/day), and Wistar rats from both control and hypertensive groups were treated with curcumin (50 or 100 mg/kg/day; gavage) or vehicle for 14 days. Blood and kidneys were collected to determine serum creatinine levels, histological alterations, oxidative stress, MMPs expression and activity, and ED1 expression. l‐NAME increased blood pressure, but both doses of curcumin treatment reduced these values. l‐NAME treatment increased creatinine levels, glomeruli area, Bowman's space, kidney MMP‐2 activity, as well as MMP‐9 and ED1 expression, and reduced the number of glomeruli. Curcumin treatment prevented the increase in creatinine levels, MMP‐2 activity, and reduced MMP‐2, MMP‐9, ED1, and superoxide levels, as well as increased superoxide dismutase activity and partially prevented glomeruli alterations. Moreover, curcumin directly inhibited MMP‐2 activity in vitro. Thus, our main findings demonstrate that curcumin reduced l‐NAME‐induced hypertension and renal glomerular alterations, inhibited MMP‐2 and MMP‐9 expression/activity, and reduced oxidative stress and inflammatory processes, which may indirectly impact hypertension‐induced renal outcomes.
- 8 September 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (7) , e4119
Curcumin Prevents Renal Damage of l‐NAME Induced Hypertension in by Reducing MMP‐2 and MMP‐9
In the present study, we investigated whether curcumin administration would interfere with the main renal features of l‐NAME‐induced hypertension model. For this purpose, we conducted both in vitro and in vivo experiments to evaluate renal indicators of inflammation, oxidative stress, and metalloproteinases (MMPs) expression/activity. Hypertension was induced by l‐NAME (70 mg/kg/day), and Wistar rats from both control and hypertensive groups were treated with curcumin (50 or 100 mg/kg/day; gavage) or vehicle for 14 days. Blood and kidneys were collected to determine serum creatinine levels, histological alterations, oxidative stress, MMPs expression and activity, and ED1 expression. l‐NAME increased blood pressure, but both doses of curcumin treatment reduced these values. l‐NAME treatment increased creatinine levels, glomeruli area, Bowman's space, kidney MMP‐2 activity, as well as MMP‐9 and ED1 expression, and reduced the number of glomeruli. Curcumin treatment prevented the increase in creatinine levels, MMP‐2 activity, and reduced MMP‐2, MMP‐9, ED1, and superoxide levels, as well as increased superoxide dismutase activity and partially prevented glomeruli alterations. Moreover, curcumin directly inhibited MMP‐2 activity in vitro. Thus, our main findings demonstrate that curcumin reduced l‐NAME‐induced hypertension and renal glomerular alterations, inhibited MMP‐2 and MMP‐9 expression/activity, and reduced oxidative stress and inflammatory processes, which may indirectly impact hypertension‐induced renal outcomes.
- 19 December 2022
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 15 (2) , 411-423
Protective Effects of Kefir Against Unpredictable Chronic Stress Alterations in Mice Central Nervous System, Heart, and Kidney
Kefir is a probiotic mixture with anxiolytic and antioxidant properties. Chronic stress can lead to anxiety disorders and increase oxidative damage in organs such as the heart and kidney. In this study, we examined whether kefir ameliorates the anxiety-like behavior of mice submitted to chronic unpredictable stress (CUS) by modulating brain-derived neurotrophic factor (BDNF) and corticosterone levels and whether kefir modifies the oxidative parameters in the heart and kidney of mice. Male Swiss mice received kefir (0.3 mL/100 g/day) or milk for 30 days (gavage). On the 10th day, the mice were submitted to CUS. Behavioral analysis was performed using the elevated plus maze and forced swimming tests. BDNF levels were analyzed in brain tissues. Heart and kidney superoxide dismutase (SOD), catalase, glutathione (GSH), thiobarbituric acid reactive substances (TBARS), 3-nitrotyrosine, metalloproteinase-2 (MMP-2), and plasma corticosterone were evaluated. Kefir reverted the CUS-induced decrease in the time spent in the open arms, the increase in grooming frequency, and decrease in the head dipping frequency, but not the reduced immobility time. CUS decreased the cerebellum BDNF levels and increased corticosterone levels, which were restored by Kefir. Neither catalase and SOD activities nor GSH, TBARS, 3-nitrotyrosine, and MMP-2 were modified by CUS in the heart. In the kidney, CUS increased 3-nitrotyrosine and MMP-2. Kefir increased the antioxidant defense in the heart and kidney of control and CUS mice. These results suggest that kefir ameliorated CUS-induced anxiety-like behavior by modulating brain BDNF and corticosterone levels. Kefir also increased the antioxidant defense of mice heart and kidney.
- 19 December 2022
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 15 (2) , 411-423
Protective Effects of Kefir Against Unpredictable Chronic Stress Alterations in Mice Central Nervous System, Heart, and Kidney
Kefir is a probiotic mixture with anxiolytic and antioxidant properties. Chronic stress can lead to anxiety disorders and increase oxidative damage in organs such as the heart and kidney. In this study, we examined whether kefir ameliorates the anxiety-like behavior of mice submitted to chronic unpredictable stress (CUS) by modulating brain-derived neurotrophic factor (BDNF) and corticosterone levels and whether kefir modifies the oxidative parameters in the heart and kidney of mice. Male Swiss mice received kefir (0.3 mL/100 g/day) or milk for 30 days (gavage). On the 10th day, the mice were submitted to CUS. Behavioral analysis was performed using the elevated plus maze and forced swimming tests. BDNF levels were analyzed in brain tissues. Heart and kidney superoxide dismutase (SOD), catalase, glutathione (GSH), thiobarbituric acid reactive substances (TBARS), 3-nitrotyrosine, metalloproteinase-2 (MMP-2), and plasma corticosterone were evaluated. Kefir reverted the CUS-induced decrease in the time spent in the open arms, the increase in grooming frequency, and decrease in the head dipping frequency, but not the reduced immobility time. CUS decreased the cerebellum BDNF levels and increased corticosterone levels, which were restored by Kefir. Neither catalase and SOD activities nor GSH, TBARS, 3-nitrotyrosine, and MMP-2 were modified by CUS in the heart. In the kidney, CUS increased 3-nitrotyrosine and MMP-2. Kefir increased the antioxidant defense in the heart and kidney of control and CUS mice. These results suggest that kefir ameliorated CUS-induced anxiety-like behavior by modulating brain BDNF and corticosterone levels. Kefir also increased the antioxidant defense of mice heart and kidney.
- 6 September 2022
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 82 (8) , 758-770
Nicotine exposure through breastfeeding affects brain‐derived neurotrophic factor and synaptic proteins levels in the brain of stressed adult female mice
Nicotine has been used during pregnancy and lactation as a tobacco harm reduction strategy. However, it is unclear whether nicotine exposure during a critical development period negatively impacts stress responses in adulthood. This study investigated how nicotine, administered via breastfeeding, affects the brain‐derived neurotrophic factor (BDNF), synaptic proteins levels, and anxiety‐like behavior in adult female mice subjected to stress. Female Swiss mice were exposed to saline or nicotine (8 mg/kg/day) through breastfeeding between their fourth and 17th postnatal days (P) via implanted osmotic mini pumps. The unpredictable chronic mild stress (UCMS) protocol was performed during their adulthood (P65) for 10 consecutive days, followed by the elevated plus maze (EPM) test 1 day after the protocol. Animals were euthanized and their blood, collected for plasma corticosterone measurements and their brain structures, dissected for BDNF and synaptic proteins analyses. We found no significant differences in corticosterone levels between groups (Saline/Non‐stress, Nicotine/Non‐stress, Saline/Stress, and Nicotine/Stress). The UCMS protocol hindered weight gain. Mice exposed to nicotine through breastfeeding with or without the UCMS protocol in adulthood showed higher grooming and head dipping frequency; decreased BDNF levels in cerebellum and striatum; increased postsynaptic density protein 95 (PSD‐95), synapsin I, and synaptophysin levels in cerebellum; and decreased PSD‐95 and synapsin I levels in brainstem. Our results indicate that nicotine exposure through breastfeeding leads to long‐lasting behavioral effects and synaptic protein changes, most of which were independent of the UCMS protocol, even after a long nicotine‐free period, highlighting the importance of further studies on nicotine exposure during development.
- 6 September 2022
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 82 (8) , 758-770
Nicotine exposure through breastfeeding affects brain‐derived neurotrophic factor and synaptic proteins levels in the brain of stressed adult female mice
Nicotine has been used during pregnancy and lactation as a tobacco harm reduction strategy. However, it is unclear whether nicotine exposure during a critical development period negatively impacts stress responses in adulthood. This study investigated how nicotine, administered via breastfeeding, affects the brain‐derived neurotrophic factor (BDNF), synaptic proteins levels, and anxiety‐like behavior in adult female mice subjected to stress. Female Swiss mice were exposed to saline or nicotine (8 mg/kg/day) through breastfeeding between their fourth and 17th postnatal days (P) via implanted osmotic mini pumps. The unpredictable chronic mild stress (UCMS) protocol was performed during their adulthood (P65) for 10 consecutive days, followed by the elevated plus maze (EPM) test 1 day after the protocol. Animals were euthanized and their blood, collected for plasma corticosterone measurements and their brain structures, dissected for BDNF and synaptic proteins analyses. We found no significant differences in corticosterone levels between groups (Saline/Non‐stress, Nicotine/Non‐stress, Saline/Stress, and Nicotine/Stress). The UCMS protocol hindered weight gain. Mice exposed to nicotine through breastfeeding with or without the UCMS protocol in adulthood showed higher grooming and head dipping frequency; decreased BDNF levels in cerebellum and striatum; increased postsynaptic density protein 95 (PSD‐95), synapsin I, and synaptophysin levels in cerebellum; and decreased PSD‐95 and synapsin I levels in brainstem. Our results indicate that nicotine exposure through breastfeeding leads to long‐lasting behavioral effects and synaptic protein changes, most of which were independent of the UCMS protocol, even after a long nicotine‐free period, highlighting the importance of further studies on nicotine exposure during development.